Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery

Trial ID: NCT06391892

Interventional - Phase 3 - Recruiting

This study evaluates the clinical prognostic impact (on DFS and OS) of liquid biopsy guided treatment vs. standard of care (physicians choice) in localized pancreatic cancer (despite because of CA 19-9 levels and computed tomography, upfront surgery is recommended by tumor board). ctDNA positive patients will receive neoadjvuant chemotherapy at current gold standard physicians choice instead of upfront surgery, because of assumed high biological risk for early recurrence.

Conditions

• Pancreatic Cancer
• Circulating Tumor Cell
• Predictive Cancer Model

Interventions

• Neoadjuvant chemotherapy instead of upfront surgery
• Upfront surgery

Eligibility

Inclusion criteria

• Informed consent
• \>18 years old
• localized pancreatic cancer to go for upfront surgery

Exclusion criteria

• synchronous secondary malignancy
• pregnancy

Sponsor

Elisabethinen Hospital, Medical University Innsbruck

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows